Annual Report

Overview

The report describes Tanvex's 2025 TX01 US commercial launch and its integration with Bora Biologics to expand CDMO services. Consolidated operating revenue reached NT$400,971 thousand, compared with NT$34,678 thousand in 2024. The company also completed its San Diego manufacturing expansion, adding two 2,000-liter single-use bioreactors.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2025
Period: 1 January 2025 – 31 December 2025
Publication date: 6 April 2026
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Provider
Level
Scope
Statement included
Metrics assured

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services